A Phase 1/2 interventional study of Ivosidenib and Nivolumab in IDH1-mutant Cholangiocarcinoma, sponsored by Servier Bio-Innovation LLC. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.
Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 243rd largest by enrollment of the 279 interventional ones that give a count, is one of 21 that started in 2023, is one of 42 in phase 1/2, and was the 255th registered.
825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.
Browse Cholangiocarcinoma studies →72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in United States, Australia, China
Ages 18+
University of Pennsylvania · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
328 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 127 · Phase 2 142 · Phase 3 24 · Phase 4 1
First in 2001; this study’s year is marked. 21 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 50 across 624 interventional studies indexed under Cholangiocarcinoma.
Median enrollment 44 across the 279 interventional studies, 230 across the 45 observational. Of the 192 that completed or were terminated, 94 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 328 have an industry lead sponsor. The 10 most frequent:
Servier Bio-Innovation LLC is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Servier Bio-Innovation LLC has 1 study filed under Cholangiocarcinoma — fewer than ten, so there is no comparison to draw.
34 of the studies in Cholangiocarcinoma with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05948475Phase 3TransThera Sciences (Nanjing), Inc.Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | 2026-12 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06723236MacroGenicsA Study of MGC028 in Participants With Advanced Solid Tumors | 2026-11 |
Add all 34 to your calendar (.ics) → With an account.
Among the 328 studies in Cholangiocarcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable or metastatic cholangiocarcinoma. The study includes two phases: the safety lead-in phase to determine the recommended combination dose (RCD) of ivosidenib in combination with immunotherapy and the dose expansion phase to assess the efficacy of ivosidenib in combination with immunotherapy. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met.
This study was terminated by the sponsor before the expansion phase began and therefore participants were only involved in the safety lead-in phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ivosidenib · Drug: Nivolumab · Drug: Ipilimumab
Drug: Ivosidenib · Drug: Nivolumab · Drug: Ipilimumab
ivosidenib taken once daily
Nivolumab taken by intravenous infusion
Ipilimumab taken by intravenous infusion
Safety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment
Occurring during the safety lead-in phase
Time frame: Through the end of Cycle 2, day 42 (Cycle 1 and 2 are each 21 days)
Safety Lead-In Phase: Number of Adverse Events (AEs)
Occurring during the safety lead-in phase
Time frame: Through study termination (approximately 1 year)
Safety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs)
Occurring during the safety lead-in phase
Time frame: Through study termination (approximately 1 year)
Safety Lead-In Phase: Number of Serious Adverse Events (SAEs)
Occurring during the safety lead-in phase
Time frame: Through study termination (approximately 1 year)
Safety Lead-In Phase: Area Under the Concentration-vs-time Curve (AUC) From 0 to Time of Last Measurable Concentration (AUC0-t)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Plasma 2-hydroxyglutarate (2-HG) Concentration
Occurring during the safety lead-in phase
Time frame: up to 3 years
Safety Lead-In Phase: AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Time to Maximum Concentration (Tmax)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Maximum Concentration (Cmax)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Trough Concentration (Ctrough)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Apparent Volume of Distribution (Vd/F)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
Safety Lead-In Phase: Apparent Clearance (CL/F)
Occurring during the safety lead-in phase
Time frame: Up to 3 years
| Milestone | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Started | 4 | 3 |
| Completed | 0 | 0 |
| Not completed | 4 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Death | 3 | 2 |
| Withdrew: Sponsor terminated the study | 1 | 0 |
Occurring during the safety lead-in phase
| DLT events | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Safety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment | 0 | 1 |
Occurring during the safety lead-in phase
| events | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Safety Lead-In Phase: Number of Adverse Events (AEs) | 71 | 27 |
Occurring during the safety lead-in phase
| Participants | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Safety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs) | 0 | 0 |
Occurring during the safety lead-in phase
| events | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Safety Lead-In Phase: Number of Serious Adverse Events (SAEs) | 3 | 2 |
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Occurring during the safety lead-in phase
No measurements were reported for this outcome.
Collected over Through study termination (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Lead-In Phase - Ivosidenib 500mg | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Safety Lead-In Phase - Ivosidenib 250mg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| Immune-mediated dermatitisSkin and subcutaneous tissue disorders | 1/4 | 2/3 |
| Immune-mediated hepatitisHepatobiliary disorders | 1/4 | 0/3 |
| PyrexiaGeneral disorders | 1/4 | 0/3 |
| Event | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg |
|---|---|---|
| FatigueGeneral disorders | 4/4 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 3/4 | 1/3 |
| Immune-mediated dermatitisSkin and subcutaneous tissue disorders | 3/4 | 1/3 |
| PruritusSkin and subcutaneous tissue disorders | 3/4 | 0/3 |
| Malignant ascitesGastrointestinal disorders | 0/4 | 2/3 |
| NauseaGastrointestinal disorders | 2/4 | 1/3 |
| Dry mouthGastrointestinal disorders | 2/4 | 0/3 |
| Oedema peripheralGeneral disorders | 2/4 | 0/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/4 | 1/3 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/4 | 1/3 |
| Age, Continuous(years) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| Mean | 60.8 ± 20.61 | 49.3 ± 15.37 | 55.9 ± 18.12 |
| Age, Customized(Participants) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| < 65 years | 2 | 2 | 4 |
| ≥ 65 years | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| White | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| Not Hispanic or Latino | 3 | 3 | 6 |
| Missing | 1 | 0 | 1 |
| Region of Enrollment(participants) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| United States | 4 | 1 | 5 |
| United Kingdom | 0 | 2 | 2 |
| BMI(kg/m^2) | Safety Lead-In Phase - Ivosidenib 500mg | Safety Lead-In Phase - Ivosidenib 250mg | Total |
|---|---|---|---|
| Mean | 26.80 ± 6.347 | 23.33 ± 2.114 | 25.31 ± 5.007 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.
Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Data sharing details ↗ · clinicaltrials.servier.com
Ran from Oct 2023 to primary completion in Nov 2024, 12 months.
Results were first posted in Feb 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ivosidenib · Nivolumab
Servier Bio-Innovation LLC